enGene Holdings Inc. (NASDAQ:ENGN) CEO Buys $57,000.00 in Stock

enGene Holdings Inc. (NASDAQ:ENGN) CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

enGene Trading Up 0.6 %

Shares of enGene stock opened at $6.50 on Friday. enGene Holdings Inc. has a 1 year low of $4.42 and a 1 year high of $43.00. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $287.08 million, a PE ratio of -3.78 and a beta of -0.68. The firm’s 50 day moving average is $6.82 and its 200 day moving average is $10.53.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities research analysts forecast that enGene Holdings Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on ENGN. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $33.67.

Hedge Funds Weigh In On enGene

Large investors have recently bought and sold shares of the company. Altitude Crest Partners Inc. bought a new stake in shares of enGene during the first quarter worth about $2,039,000. SR One Capital Management LP bought a new position in enGene in the 2nd quarter valued at approximately $4,715,000. Omega Fund Management LLC acquired a new stake in enGene during the 4th quarter worth approximately $10,441,000. Logos Global Management LP grew its holdings in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in enGene in the 1st quarter valued at approximately $17,095,000. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.